David J Jackson
Overview
Explore the profile of David J Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackson D, Pelaia G, Emmanuel B, Tran T, Cohen D, Shih V, et al.
Immunotherapy
. 2025 Feb;
17(2):71-81.
PMID: 39931841
No abstract available.
2.
Larenas-Linnemann D, Rhee C, Altraja A, Busby J, Tran T, Wang E, et al.
Tuberc Respir Dis (Seoul)
. 2025 Feb;
PMID: 39915034
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry...
3.
Jackson D, Heaney L, Humbert M, Kent B, Shavit A, Hiljemark L, et al.
Immunotherapy
. 2025 Jan;
16(20-22):1175-1184.
PMID: 39780731
No abstract available.
4.
Rupani H, Chaudhuri R, Jackson D, Moyses H, Kurukulaaratchy R, Haitchi H, et al.
J Allergy Clin Immunol
. 2024 Nov;
155(1):236-237.
PMID: 39520415
No abstract available.
5.
Khaleva E, Brightling C, Eiwegger T, Altraja A, Begin P, Blumchen K, et al.
Eur Respir J
. 2024 Nov;
PMID: 39510551
Background: We have previously developed Core Outcome Measures sets for Severe Asthma (COMSA) by multi-stakeholder consensus. There are no patient-centred tools to quantify response to biologics for severe asthma. We...
6.
Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Boussad R, Veront C, et al.
Allergy
. 2024 Oct;
80(3):715-737.
PMID: 39466641
Background: Severe refractory, neutrophilic asthma remains an unsolved clinical problem. STING agonists induce a neutrophilic response in the airways, suggesting that STING activation may contribute to the triggering of neutrophilic...
7.
Jackson D, Wechsler M, Brusselle G, Buhl R
Allergy
. 2024 Oct;
79(11):2943-2952.
PMID: 39396109
Eosinophilic asthma is characterized by frequent exacerbations, poor symptom control and accelerated lung function decline. It is now recognized that the immune response underlying eosinophilic asthma involves a complex network...
8.
Sun N, Ogulur I, Mitamura Y, Yazici D, Pat Y, Bu X, et al.
Allergy
. 2024 Oct;
79(12):3192-3237.
PMID: 39370939
The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives...
9.
Wechsler M, Brusselle G, Virchow J, Bourdin A, Kostikas K, Llanos J, et al.
Eur Respir J
. 2024 Sep;
64(6).
PMID: 39326921
Background: In asthma, clinical response is characterised by disease improvement with treatment, whereas clinical remission is characterised by long-term disease stabilisation with or without ongoing treatment. The proportions of patients...
10.
Jackson D, Wechsler M, Jackson D, Bernstein D, Korn S, Pfeffer P, et al.
N Engl J Med
. 2024 Sep;
391(24):2337-2349.
PMID: 39248309
Background: Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. Methods: In these phase 3A, randomized, placebo-controlled replicate trials, we...